Skip to main content
Log in

Development of 166Ho-phytate Complex for Radiosynovectomy

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Background

66Ho-chloride was obtained by bombardment of natural Ho(NO3)3 dissolved in acidic media using thermal neutron flux (4-5 × 1013 n.cm-2.s-1).

Methods

166Ho-holmium chloride (185 MBq) was used successfully for preparation of 166Ho-phytate complex with high radiochemical purity (>99.9 %, ITLC, MeOH: H2O: acetic acid, 4: 4: 2, as mobile phase). The complex stability and viscosity were checked in the final solution up to 2 days. The prepared complex solution (60 μCi/100 μl) was injected intraarticularly to male rat knee joints. Leakage of radioactivity from the injection site and its distribution in organs were investigated up to 2 days.

Results

Approximately all of the injected dose had remained in the injection site 2 days after injection.

Conclusion

The complex was proved to be a feasible agent for cavital radiotherapy in oncology and rheumatology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. European Association of Nuclear Medicine (EANM) Procedure Guidelines for Radiosynovectomy, Guidelines issued date: October 4, 2002.

  2. Kropácek M, Melichar F, Henková K, Konopková M. Preparation of holmium-166 labelled macroaggregates for radionuclide synovectomy. Nucl Med Rev Cent East Eur. 2003;6(1):1–4.

    PubMed  Google Scholar 

  3. Suzuki YS, Momose Y, Higashi N, Shigematsu A, Park KB, Kim YM, et al. Biodistribution and kinetics of holmium-166-phytate complex (DW-166HC) in rats and mice. J Nucl Med. 1998;39:2161–6.

    PubMed  CAS  Google Scholar 

  4. Breitz H, Wendt R, Stabin M, Bouchet L, Wessels B. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biother Radiopharm. 2003;18(2):225–30.

    Article  PubMed  CAS  Google Scholar 

  5. Majali MA, Saxena SK, Joshi SH, Unni PR, Ramamoorthy N. Potential 166Ho radiopharmaceuticals for endovascular radionuclide therapy. II. Preparation and evaluation of 166Ho-DTPA. Nucl Med Commun. 2001;22(1):97–103.

    Article  PubMed  CAS  Google Scholar 

  6. Das T, Chakraborty S, Sarma HD, Venkatesh M, Banerjee S. Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. Nucl Med Commun. 2009;30(5):362–7.

    Article  PubMed  Google Scholar 

  7. Chung YL, Lee JD, Bang D, Lee JB, Park KB, Lee MG. Treatment of Bowen's disease with a specially designed radioactive skin patch. Eur J Nucl Med. 2000;27(7):842–6.

    Article  PubMed  CAS  Google Scholar 

  8. Manual for Reactor Produced Radioisotopes, IAEA, Vienna, 2003, IAEA-TECDOC-1340, ISBN 92–0–101103–2, ISSN 1011–4289, © IAEA, 2003, pp.71, Printed by the IAEA in Austria, January 2003.

Download references

Conflict of Interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Amir R. Jalilian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jalilian, A.R., Anvari, A., Bahrami-Samani, A. et al. Development of 166Ho-phytate Complex for Radiosynovectomy. Nucl Med Mol Imaging 45, 87–92 (2011). https://doi.org/10.1007/s13139-010-0048-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-010-0048-6

Keywords

Navigation